Drug Profile
Edecesertib - Gilead Sciences
Alternative Names: GS-5718; Interleukin-1 receptor-associated kinase 4 inhibitor - Gilead SciencesLatest Information Update: 11 Aug 2023
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Class Anti-inflammatories; Antirheumatics; Skin disorder therapies; Small molecules
- Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cutaneous lupus erythematosus; Systemic lupus erythematosus
- Phase I Inflammation
- Discontinued Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 11 Aug 2023 Chemical structure information added
- 09 Aug 2023 Phase-II clinical trials in Systemic lupus erythematosus in USA (PO) prior to August 2023 (Gilead sciences pipeline, August 2023)
- 17 Apr 2023 Phase-II clinical trials in Cutaneous lupus erythematosus (In the elderly, In adults) in USA (PO) (NCT05629208)